Research Article
Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer
Table 7
Summary of top pathways returned by KEGG using CPDB for early- and late-stage cancer.
| Early-stage NSCLC | Term | Effective size | % of overlap | value |
| Leukocyte transendothelial migration | 118 | 3.4% | | Glycolysis/gluconeogenesis | 66 | 4.5% | 0.000250 | Epithelial cell signaling in Helicobacter pylori infection | 68 | 4.4% | 0.000273 | HIF-1 signaling pathway | 106 | 2.8% | 0.00100 | Tight junction | 134 | 2.2% | 0.00197 | Cell adhesion molecules (CAMs) | 147 | 2.0% | 0.00257 |
| Late-stage NSCLC | Term | Effective size | % of overlap | value |
| Cell cycle | 124 | 9.7% | | Oocyte meiosis | 110 | 7.3% | | Progesterone-mediated oocyte maturation | 86 | 7.0% | | DNA replication | 36 | 8.3% | 0.00100 | Epstein-Barr virus infection | 203 | 2.5% | 0.00512 | Viral carcinogenesis | 206 | 2.4% | 0.00544 | p53 signaling pathway | 68 | 4.4% | 0.00620 | Measles | 134 | 3.0% | 0.00630 | Hepatitis B | 146 | 2.7% | 0.00849 |
|
|